HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

MLA

Jiryeon Jang, et al. “HER2-Positive Gastric Cancer with Concomitant MET and/or EGFR Overexpression: A Distinct Subset of Patients for Dual Inhibition Therapy.” International Journal of Cancer, vol. 136, Sept. 2014, pp. 1629–35. EBSCOhost, https://doi.org/10.1002/ijc.29159.

APA

Jiryeon Jang, Won Ki Kang, Cheol Keun Park, Min-Gew Choi, Jung Yong Hong, Min-Ji Kim, Seonwoo Kim, Se Hoon Park, In-Gu Do, Joon Oh Park, Tae Sung Sohn, Jeeyun Lee, Sung Kim, Sang Yun Ha, Kyoung-Mee Kim, & Jae Moon Bae. (2014). HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy. International Journal of Cancer, 136, 1629–1635. https://doi.org/10.1002/ijc.29159

Chicago

Jiryeon Jang, Won Ki Kang, Cheol Keun Park, Min-Gew Choi, Jung Yong Hong, Min-Ji Kim, Seonwoo Kim, et al. 2014. “HER2-Positive Gastric Cancer with Concomitant MET and/or EGFR Overexpression: A Distinct Subset of Patients for Dual Inhibition Therapy.” International Journal of Cancer 136 (September): 1629–35. doi:10.1002/ijc.29159.